We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current RCUS market cap is 1.26B. The company's latest EPS is USD -3.3754 and P/E is -4.10.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 25M | 29M | 32M | 31M | 145M |
| Operating Income | -86M | -83M | -80M | -91M | 4M |
| Net Income | -80M | -75M | -71M | -81M | -4M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 15M | 77.52M | 382.88M | 112M | 117M |
| Operating Income | -89.91M | -124.85M | 54.25M | -280M | -340M |
| Net Income | -84.71M | -122.86M | 52.83M | -267M | -307M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.25B | 1.22B | 1.19B | 1.1B | 1.29B |
| Total Liabilities | 654M | 654M | 671M | 633M | 586M |
| Total Equity | 600M | 566M | 520M | 462M | 707M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 203.11M | 772.29M | 1.59B | 1.35B | 1.1B |
| Total Liabilities | 39.27M | 269.99M | 750.45M | 688M | 633M |
| Total Equity | 163.84M | 502.3M | 841.45M | 657M | 462M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -98M | -155M | -218M | -306M | -2M |
| Investing | 129M | 155M | 166M | 194M | -169M |
| Financing | 1M | 24M | 30M | 33M | 229M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -73.46M | 111.17M | -256.17M | 438M | -306M |
| Investing | 59.21M | -434.37M | -3.87M | -413M | 194M |
| Financing | 1.12M | 438.68M | 237.34M | 33M | 33M |
| Market Cap | 1.26B |
| Price to Earnings Ratio | -4.10 |
| Price to Sales Ratio | 10.77 |
| Price to Cash Ratio | 9.92 |
| Price to Book Ratio | 2.73 |
| Dividend Yield | - |
| Shares Outstanding | 90.95M |
| Average Volume (1 week) | 549.15k |
| Average Volume (1 Month) | 1M |
| 52 Week Change | -36.85% |
| 52 Week High | 25.47 |
| 52 Week Low | 12.95 |
| Spread (Intraday) | 1.39 (9.13%) |
| Company Name | Arcus Biosciences Inc |
| Address |
2140 s dupont hwy camden, delaware 19934 |
| Website | https://www.arcusbio.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
